Gland Pharma (GLAND) Q4 24/25 earnings summary

Executive summary

• FY25 was a pivotal year marked by strategic realignment, manufacturing and R&D investments, and expansion into emerging and high-value markets, including complex injectables and GLP-1.

• Consolidated revenue for FY25 was ₹56,165 million, down 1% year-over-year; Q4 revenue was ₹14,249 million, down 7% year-over-year but up 3% sequentially.

• EBITDA margin improved to 24% in Q4 FY25, with base business EBITDA margin at 38% due to US portfolio volume and new launches.

• Cenexi's turnaround is underway, shifting from low-value, high-volume to high-value products, with capacity enhancements and automation.

• Final dividend of ₹18 per share recommended for FY25, subject to shareholder approval.

Financial highlights

• FY25 consolidated EBITDA was ₹12,689 million, down 5% year-over-year; PAT was ₹6,985 million, down 10% year-over-year.

• Q4 FY25 EBITDA was ₹3,475 million (24% margin); Q4 PAT was ₹1,865 million, down 3% year-over-year.

• Gross profit for FY25 was ₹35,261 million (62% margin); Q4 gross margin rose to 66%.

• Cash and bank balances at year-end were ₹25,562 million; net cash at ₹22,870 million.

• R&D expenses for FY25 were ₹1,922 million (4.7% of revenue); 31 new product launches in FY25.

Outlook and guidance

• Consolidated revenue growth guidance for FY26 is mid-teens, with low-20% growth expected in subsequent years.

• Cenexi expected to achieve positive EBITDA by Q3 FY26 and double-digit EBITDA margin by FY27.

• Revenue generation from biologics CDMO collaboration with DRL expected from FY26.

• Commercial production of new vaccine and expanded ampoule capacity expected in FY26.

• Strategic focus on accelerating growth in RoW and India, deepening US presence, and executing Cenexi turnaround.